Annovis Bio files for patent covering use of lead drug; shares rise

Annovis Bio

01/02/2023 16:42

** Shares of drug developer Annovis Bio  ANVS.N  rise 8% to
$17.84
    ** Co files a patent application covering the use of its
lead compound, buntanetap, or its analogs for preventing,
treating, or delaying the onset of mental illnesses  
    ** Buntanetap is being tested to treat multiple neurological
diseases including Alzheimer's and Parkinson's disease -ANVS    
    ** Buntanetap is an oral drug candidate which potentially
targets and inhibits multiple proteins responsible for a host of
nervous system diseases including mental illnesses -ANVS
    ** Including session moves, stock has rise ~16.2% over the
past 12 months 
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))